Risk of ovarian cancer in women who give birth after assisted reproductive technology (ART)—a registry-based Nordic cohort study with follow-up from first pregnancy

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Background: There is concern that assisted reproductive technology (ART) may increase ovarian cancer risk, but previous studies are inconclusive. We compared ovarian cancer risk for women who gave birth after ART vs natural conception. Methods: Through linkage of nationwide registry data, we followed 3,303,880 initially nulliparous women in Denmark (1994–2014), Finland (1990–2014), Norway (1984–2015) and Sweden (1985–2015) from first pregnancy ≥22 weeks to ovarian cancer, emigration, death or end of follow-up (2014/2015). We estimated hazard ratios (HRs), adjusting for age, parity, maternal birth year and country, and for body mass index and smoking in subsamples. Results: Mean age at first birth was 27.7 years. During a mean follow-up of 14.4 person-years, 2683 participants (0.08%) developed ovarian cancer; 135 after ART and 2548 after natural conception only (incidence rates 11.6 and 5.5 per 100,000 person-years, respectively). The risk was higher for women who ever gave birth after ART (HR 1.70, 95% confidence interval 1.42–2.03) compared to natural conception. Associations were stronger for conventional in vitro fertilisation than for intracytoplasmic sperm injection. Conclusions: Among parous women, ART-conception was associated with a higher risk of ovarian cancer than natural conception. Further studies should decipher whether this is causal or confounded by infertility or other factors.

OriginalsprogEngelsk
TidsskriftBritish Journal of Cancer
Vol/bind128
Udgave nummer5
Sider (fra-til)825-832
Antal sider8
ISSN0007-0920
DOI
StatusUdgivet - 2023

Bibliografisk note

Funding Information:
The project was supported by a grant from the Norwegian Cancer Society [grant number 182356–2016]. The establishment of the CoNARTaS cohort has additionally been supported by the Nordic Trial Alliance: a pilot project jointly funded by the Nordic Council of Ministers and NordForsk [grant number 71450], the Central Norway Regional Health Authorities [grant number 46045000], the Nordic Federation of Obstetrics and Gynaecology [grant numbers NF13041, NF15058, NF16026 and NF17043], the Interreg Öresund-Kattegat-Skagerrak European Regional Development Fund (ReproUnion project).

Publisher Copyright:
© 2022, The Author(s), under exclusive licence to Springer Nature Limited.

ID: 340551960